- ?? Blog ActionCovid1984.org
- ?? Irish Examiner
- Inverse
- ?? Gript media
- Blake-Lemoine - LaMBDA
- ?? Over Dee Wall
- The Defender News
- ?? BreakingNews.ie
- Dr Vernon Coleman
- Rebel News
- Vaccine Choice Canada NEWS
- SHFT Plan
- The Expose
- ?? Robert Pierzyński PJ
- James Roguskii - Substack
- ?? The Burkean
- Liberty Tactics IM
- stewpeters.com
- Technocracy News
- Interesting Engineering
- ?? Media Hub Ireland
- ?? The Irish Inquiry
- ?? Andy Heasman
- ?? GriptMedia
- ?? WeThePeople.ie
- ?? Action-Covid-1984
- ?? Lets wake up our Capital
- ?? Lets Wake Up Call!!!
- WW Freedom Rallies
- Piers Corbyn
- ?? Tracey OMahony
- ?? The Irish Git
- eIRe is falling
- Peter Madden Channel
- rish Farmers,Food & Family
- Gemma O'Doherty
What's new
What's new
Report - Industry stakeholders and EU network experts surveys on early engagement fostering innovation
Report - Industry stakeholders and EU network experts surveys on early engagement fostering innovation
23 April 2025
Human medicines European public assessment report (EPAR): Pyzchiva, ustekinumab, Date of authorisation: 19/04/2024, Revision: 6, Status: Authorised
Human medicines European public assessment report (EPAR): Pyzchiva, ustekinumab, Date of authorisation: 19/04/2024, Revision: 6, Status: Authorised
23 April 2025
Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 8, Status: Authorised
Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 8, Status: Authorised
23 April 2025
Human medicines European public assessment report (EPAR): Nilotinib Accord, nilotinib, Date of authorisation: 22/08/2024, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Nilotinib Accord, nilotinib, Date of authorisation: 22/08/2024, Revision: 1, Status: Authorised
23 April 2025
Human medicines European public assessment report (EPAR): Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG), telmisartan, Date of authorisation: 16/12/1998, Revision: 32, Status: Authorised
Human medicines European public assessment report (EPAR): Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG), telmisartan, Date of authorisation: 16/12/1998, Revision: 32, Status: Authorised
23 April 2025
Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Date of authorisation: 29/08/2008, Revision: 53, Status: Authorised
Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Date of authorisation: 29/08/2008, Revision: 53, Status: Authorised
23 April 2025
Human medicines European public assessment report (EPAR): Ngenla, somatrogon, Date of authorisation: 14/02/2022, Revision: 5, Status: Authorised
Human medicines European public assessment report (EPAR): Ngenla, somatrogon, Date of authorisation: 14/02/2022, Revision: 5, Status: Authorised
23 April 2025
Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 47, Status: Authorised
Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 47, Status: Authorised
23 April 2025
Human medicines European public assessment report (EPAR): Uzpruvo, ustekinumab, Date of authorisation: 05/01/2024, Revision: 6, Status: Authorised
Human medicines European public assessment report (EPAR): Uzpruvo, ustekinumab, Date of authorisation: 05/01/2024, Revision: 6, Status: Authorised
23 April 2025